Polyol pathway and RAGE: a central metabolic and signaling axis in diabetic complications

References

• Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat. Rev. Drug Discov.8(5), 417–429 (2009).
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response – the evidence mounts. J. Leukoc. Biol.86, 505–512 (2009).
   PubMed Web of Science ®Google Scholar
• Kaneko M, Bucciarelli L, Hwang YC et al. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann. NY Acad. Sci.1043, 702–709 (2005).
   PubMed Web of Science ®Google Scholar
• Williamson JR, Chang K, Frangos M et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes42(6), 801–813 (1993).
   PubMed Web of Science ®Google Scholar
• Turk Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol. Res. (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Niwa T. 3-deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J. Chromatogr.731(1), 23–36 (1999).
   Web of Science ®Google Scholar
• Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical Type 1 diabetes. Diabetologia48(8), 1590–1603 (2005).
   PubMed Web of Science ®Google Scholar
• Jono T, Nagai R, Lin X et al. N-e-(carboxymethyl)lysine and 3-DG-imidazolone are major AGE structures in protein modification by 3-deoxyglucosone. J. Biochem.136(3), 351–358 (2004).
   PubMed Web of Science ®Google Scholar
• Li W, Hamada Y, Nakashima E et al. Suppression of 3-deoxyglucosone and heparin-binding epidermal growth factor-like growth factor mRNA expression by aldose reductase inhibitor in rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun.314(2), 370–376 (2004).
   PubMed Web of Science ®Google Scholar
• Hamada Y, Nakamura J, Naruse K et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of Ne-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care23(10), 1539–1544 (2000).
   PubMed Web of Science ®Google Scholar
• Nakamura N, Yamazaki K, Satoh A et al. Effects of epalrestat on plasma levels of advanced glycation end products in patients with Type 2 diabetes. In Vivo17(2), 177–180 (2003).
   PubMed Web of Science ®Google Scholar
• Kilhovd BK, Giardino I, Torjesen PA et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with Type 2 diabetes. Metabolism52(2), 163–167 (2003).
   PubMed Web of Science ®Google Scholar
• Richard JP. Mechanism for the formation of methylglyoxal from triosephosphates. Biochem. Soc. Trans.21(2), 549–553 (1993).
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification – a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol.27, 565–573 (1996).
   PubMedGoogle Scholar
• Dhar A, Desai K, Kazachmov M, Yu P, Wu L. Methylglyoxal production in vascular smooth muscle cells from different metabolic precursors. Metabolism57(9), 1211–1220 (2008).
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem. Biol. Interact.111–112, 137–151 (1998).
   PubMed Web of Science ®Google Scholar
• Phillips SA, Mirrlees D, Thornalley PJ. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem. Pharmacol.46(5), 805–811 (1993).
   PubMed Web of Science ®Google Scholar
• Diaz-Flores M, Ibanez-Hernandez MA, Glavan RE et al. Glucose-6-phosphate dehydrogenase activity and NADPH/NADP+ ratio in liver and pancreas are dependent on the severity of hyperglycemia in rat. Life Sci.78(22), 2601–2607 (2006).
   PubMed Web of Science ®Google Scholar
• Yang MS, Chan HW, Yu LC. Glutathione peroxidase and glutathione reductase activities are partially responsible for determining the susceptibility of cells to oxidative stress. Toxicology226(2–3), 126–130 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest.91(5), 2155–2168 (1993).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest.96(3), 1395–1403 (1995).
   PubMed Web of Science ®Google Scholar
• Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem.283(40), 27255–27269 (2008).
   PubMed Web of Science ®Google Scholar
• Kislinger T, Fu, C, Huber B et al. N(e)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem.274(44), 31740–31749 (1999).
   PubMed Web of Science ®Google Scholar
• Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy – are these receptors valid therapeutic targets. Curr. Drug Targets10(1), 42–50 (2009).
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes46(2), 292–300 (1997).
   PubMed Web of Science ®Google Scholar
• Hwang YC, Kaneko M, Bakr S et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J.18(11), 1192–1199 (2004).
   PubMed Web of Science ®Google Scholar
• Aleshin A, Ananthakrishnan R, Li Q et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and Stat signaling in a murine model. Am. J. Physiol. Heart Circ. Physiol.294, 1823–1832 (2008).
   Google Scholar
• Chang JS, Wendt T, Qu W et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation endproducts. Circ. Res.102, 905–913 (2008).
   PubMed Web of Science ®Google Scholar
• Taguchi A, Blood DC, del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature405, 354–360 (2000).
   PubMed Web of Science ®Google Scholar
• Zill H, Gunther R, Erbersdobler HF, Folsch UR, Faist V. RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem. Biophys. Res. Commun.288, 1108–1111 (2001).
   PubMed Web of Science ®Google Scholar
• Dukic-Stefanovic S, Gasic-Milenkovic J, Deuther-Conrad W, Munch G. Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). J. Neurochem.87, 44–55 (2003).
   PubMed Web of Science ®Google Scholar
• Harja E, Bu DX, Hudson BI et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J. Clin. Invest.118, 183–194 (2008).
   PubMed Web of Science ®Google Scholar
• Guo J, Ananthakrishnan R, Qu W et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J. Am. Soc. Nephrol.19, 961–972 (2008).
   PubMed Web of Science ®Google Scholar
• Origlia N, Righi M, Capsoni S et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction. J. Neurosci.28, 3521–3530 (2008).
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Yan SF, Yan SD et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest.111, 959–972 (2003).
   PubMed Web of Science ®Google Scholar
• Reddy MA, Li SL, Sahar S et al. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation endproducts in vascular smooth muscle cells. J. Biol. Chem.281, 13685–13693 (2006).
   PubMed Web of Science ®Google Scholar
• Vincent AM, Perrone L, Sullivan KA et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology148, 548–558 (2007).
   PubMed Web of Science ®Google Scholar
• Fukami K, Ueda S, Yamaghishi S et al. AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type 1 receptor interaction. Kidney Int.66, 2137–2147 (2004).
   PubMed Web of Science ®Google Scholar
• Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem.274, 19919–19924 (1999).
   PubMed Web of Science ®Google Scholar
• Sorci G, Riuzzi F, Arcuri C, Giambanco I, Donato R. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol. Cell. Biol.24, 4880–4894 (2004).
   PubMed Web of Science ®Google Scholar
• Hudson BI, Kalea AZ, Del Mar Arriero M et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem.283, 34457–34468 (2008).
   PubMed Web of Science ®Google Scholar
• Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation endproducts (RAGE) directly binds to ERK by a D-domain like docking site. FEBS Lett.550, 107–113 (2003).
   PubMed Web of Science ®Google Scholar
• Tang WH, Wu S, Wong TM, Chung SK, Chung SS. Polyol pathway mediates iron-induced oxidative injury in ischemic-reperfused rat heart. Free Radic. Biol. Med.45(5), 602–610 (2008).
   PubMed Web of Science ®Google Scholar
• Qui L, Wu X, Chau JF et al. Aldose reductase regulates hepatic peroxisome proliferator-activated receptor a phosphorylation and activity to impact lipid homeostasis. J. Biol. Chem.283(25), 17175–17183 (2008).
   PubMed Web of Science ®Google Scholar
• Jiang T, Che Q, Lin Y, Li H, Zhang N. Aldose reductase regulates TGF-β1-induced production of fibronectin and type IV collagen in cultured rat mesangial cells. Nephrology11(2), 105–112 (2006).
   PubMed Web of Science ®Google Scholar
• Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates Jak/STAT signaling: a novel axis in myocardial ischemic injury. FASEB J.19(7), 795–797 (2005).
   PubMed Web of Science ®Google Scholar
• Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem.277(35), 32063–32070 (2002).
   PubMed Web of Science ®Google Scholar
• Trueblood NA, Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am. J. Physiol.275, H75–H82 (1998).
   Google Scholar
• Ramasamy R, Trueblood NA, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am. J. Physiol.275, H195–H203 (1998).
   PubMed Web of Science ®Google Scholar
• Hwang YC, Sato S, Tsai J et al. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J.16, 243–245 (2002).
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Liu H, Oates PJ, Schaefer S. Attenuation of ischemia induced increases in sodium and calcium by an aldose reductase inhibitor zopolrestat. Cardiovasc. Res.42, 130–139 (1999).
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan R, Kaneko M, Hwang YC et al. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondria permeability transition pore. Am. J. Physiol. Heart Circ. Physiol.296, H333–H341 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson BF, Nesto RW, Pfeifer MA et al. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care27(2), 448–454 (2004).
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Kaneko M, Ananthakrishnan R et al. Receptor for advanced glycation endproducts: key modulator of myocardial ischemic injury. Circulation113(9), 1226–1234 (2006).
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Ananthakrishnan R, Hwang YC et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes57(7), 1941–1951 (2008).
   PubMed Web of Science ®Google Scholar
• Sun M, Yokoyama M, Ishiwata T, Asano G. Deposition of advanced glycation endproducts (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int. J. Exp. Pathol.79(4), 207–222 (1998).
   PubMed Web of Science ®Google Scholar
• Kato T, Yamashita T, Sekiguchi A et al. AGEs–RAGE system mediates atrial structural remodeling in the diabetic rat. J. Cardiovasc. Electrophysiol.19(4), 415–420 (2008).
   PubMed Web of Science ®Google Scholar
• Andrassy M, Volz HC, Igwe JC et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation117(25), 3216–3226 (2008).
   PubMed Web of Science ®Google Scholar
• Gao ZQ, Yang C, Wang YY et al. RAGE upregulation and nuclear factor kB activation associated with ageing rat cardiomyocyte dysfunction. Gen. Physiol. Biophys.27(3), 152–158 (2008).
   PubMed Web of Science ®Google Scholar
• Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin induced cardiomyocyte dysfunction via the receptor for advanced glycation endproducts. Circ. Res.102(10), 1239–1246 (2008).
   PubMed Web of Science ®Google Scholar
• Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-α induced expression of adhesion molecules in endothelial cells. FASEB J.18(11), 1209–1218 (2004).
   PubMed Web of Science ®Google Scholar
• Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol.28(6), 1137–1143 (2008).
   PubMed Web of Science ®Google Scholar
• Dan Q, Wong R, Chung SK, Chung SS, Lam KS. Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion. Life Sci.76(4), 445–459 (2004).
   PubMed Web of Science ®Google Scholar
• Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem.277(35), 32063–32070 (2002).
   PubMed Web of Science ®Google Scholar
• Ruef J, Liu SQ, Bode C et al. Involvement of aldose reductase in vascular smooth muscle growth and lesion formation after arterial injury. Arterioscler. Thromb. Vasc. Biol.20(7), 1745–1752 (2000).
   PubMed Web of Science ®Google Scholar
• Vikramadithyan RK, Hu Y, Noh HL et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest.115(9), 2434–2443 (2005).
   PubMed Web of Science ®Google Scholar
• Noh H-L, Hu Y, Park T-S et al. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J. Pharmacol. Exp. Ther.328(2), 496–503 (2009).
   PubMed Web of Science ®Google Scholar
• Burke AP, Kolodgie FD, Zieske A et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol.24(7), 1266–1271 (2004).
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med.4(9), 1025–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Kislinger T, Tanji N, Wendt T et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol.21(6), 905–910 (2001).
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation106(22), 2827–2835 (2002).
   PubMed Web of Science ®Google Scholar
• Wendt T, Harja E, Bucciarelli L et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of Type 2 diabetes. Atherosclerosis185(1), 70–77 (2006).
   PubMed Web of Science ®Google Scholar
• Soro-Paavonen A, Watson AM, Li J et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes57(9), 2461–2469 (2008).
   PubMed Web of Science ®Google Scholar
• Harja E, Bu DX, Hudson BI et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J. Clin. Invest.118(1), 183–194 (2008).
   PubMed Web of Science ®Google Scholar
• Sun L, Ishida T, Yasuda T et al. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc. Res.82(2), 371–381 (2009).
   PubMed Web of Science ®Google Scholar
• Mylari BL, Beyer TA, Siegel TW. A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxyO2(5H)-oxopyrrole-4-carboxylate, and its congeners. J. Med. Chem.34, 1011–1018 (1991).
   PubMed Web of Science ®Google Scholar
• Sarges R, Oates PJ. Aldose reductase inhibitors: recent developments. Prog. Drug Res.40, 99–161 (1993).
   PubMedGoogle Scholar
• Alexiou P, Pegkidou K, Chatzopoulou M, Nocolaou I, Demopoulos VJ. Aldose reductase enzyme and its implication to major health problems of the 21st century. Curr. Med. Chem.16(6), 734–752 (2009).
   PubMed Web of Science ®Google Scholar
• Bank N, Mower P, Aynedjian HS, Wilkes BM, Silverman S. Sorbinil prevents glomerular hyperperfusion in diabetic rats. Am. J. Physiol.256, F1000–F1006 (1989).
   Google Scholar
• Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR. Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic NADH/NAD+. Kidney Int.41, 778–788 (1992).
   PubMed Web of Science ®Google Scholar
• Beyer-Mears A, Murray FT, Cruz E, Roundtree J, Sciadini M. Comparison of sorbinil and ponalrestat diminution of proteinuria in the BB rat. Pharmacology45, 285–291 (1992).
   PubMed Web of Science ®Google Scholar
• Itagaki I, Shimizu K, Kamanaka Y et al. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats. Diabetes Res. Clin. Pract.25, 147–154 (1994).
   PubMed Web of Science ®Google Scholar
• Donnelly SM, Zhou XP, Huang JT, Whiteside CI. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat. Biochem. Cell Biol.74, 355–362 (1996).
   PubMed Web of Science ®Google Scholar
• Keogh RJ, Dunlop ME, Larkins RG. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C and phospholipase A2 activation. Metabolism46, 41–47 (1997).
   PubMed Web of Science ®Google Scholar
• Daniels BS, Hosetter TH. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes38, 981–986 (1989).
   PubMed Web of Science ®Google Scholar
• Osterby R, Gundersen HJ. Glomerular basement membrane thickening in streptozotocin-diabetic rats despite treatment with an aldose reductase inhibitor. J. Diabetes Complications3, 149–153 (1989).
   Google Scholar
• Yamaoka T, Nishimura C, Yamashita K et al. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia38, 255–261 (1995).
   PubMed Web of Science ®Google Scholar
• Dan Q, Wong RL, Yin S, Chung SK, Chung SS, Lam KS. Interaction between the polyol pathway and non-enzymatic glycation on mesangial cell gene expression. Nephron Exp. Nephrol.98(3), e89–e99 (2004).
   Google Scholar
• Passariello N, Sepe J, Marrazzo G et al. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDMM subjects with nephropathy. Diabetes Care16, 789–795 (1993).
   PubMed Web of Science ®Google Scholar
• Iso K, Tada H, Koboki K, Inokuchi T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic subjects. J. Diabetes Complications15, 241–244 (2001).
   PubMed Web of Science ®Google Scholar
• Zopolrestat Diabetic Nephropathy Study Group. Effect of zopolrestat on urinary albumin excretion rate in Type 1 diabetic subjects. Presented at: The Annual Meeting of the American Society of Nephrology 4–9 November, PA, USA (2008) (Abstract).
   Google Scholar
• Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol.11, 1656–1666 (2000).
   PubMed Web of Science ®Google Scholar
• Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol.162(4), 1123–1127 (2003).
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A, Denner L, Schrijvers BF et al. Long-term renal effects of a neutralizing RAGE antibody in obese Type 2 diabetic mice. Diabetes53, 166–172 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen LJ, Denner L, Schrijvers BF, Tilton RG, Rasch R, Flyvbjerg A. Renal effects of a neutralizing RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol.188, 493–501 (2006).
   PubMed Web of Science ®Google Scholar
• Myint KM, Yamamoto Y, Doi T et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes55, 2510–2522 (2006).
   PubMed Web of Science ®Google Scholar
• Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, resilient. Exp. Diabetes Res.2007, 61038 (2007).
   PubMedGoogle Scholar
• Schemmel KE, Padiyara RS, D’Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J. Diabetes Complications DOI: 10.1016/j.jdiacomp.2009.07.005 (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Barile GR, Schmidt AM. RAGE and its ligands in retinal disease. Curr. Mol. Med.7, 758–765 (2007).
   PubMed Web of Science ®Google Scholar
• Toth C, Martinez J, Zochodne DW. RAGE, diabetes and the nervous system. Curr. Mol. Med.7, 766–776 (2007).
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev.26, 380–392 (2005).
   PubMed Web of Science ®Google Scholar
• Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Exp. Opin. Invest. Drugs8, 2095–2119 (1999).
   PubMedGoogle Scholar
• Neatmat-Allah M, Feeney SA, Savage DA et al. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus. Diabetic Med.18, 906–914 (2001).
   PubMed Web of Science ®Google Scholar
• Hudson BI, Stickland MH, Futers TS, Grant PJ. Effect of novel polymorphisms of the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes50(6), 1505–1511.
   PubMed Web of Science ®Google Scholar
• Kankova K, Stejskalova A, Hertlova M, Znojil V. Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in Type 2 diabetes mellitus. Nephrol. Dial. Transplant.20(6), 1093–1102 (2005).
   PubMed Web of Science ®Google Scholar
• PKC-DRS2 Group, Aiello LP, Davis MD et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113(12), 2221–2230 (2006).
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Konvalinka A, Zinman B et al. Effect of protein kinase C b inhibition on renal hemodynamic function and urinary biomarkers in humans with Type 1 diabetes: a pilot study. Diabetes Care32(1), 91–93 (2009).
   PubMed Web of Science ®Google Scholar
• Rashba EJ, Reich EP, Janeway CA, Sherwin RS. Type 1 diabetes mellitus: an imbalance between effector and regulatory T cells? Acta Diabetol.30(2), 61–69 (1993).
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol.25(1), 4–7 (2004).
   PubMed Web of Science ®Google Scholar
• Kaufmann JJ, Langdon EA, Stein JJ, Burt FB. Cancer of the bladder. Combined 5-fluorouracil and cobalt-60 teletherapy. Calif. Med.101, 334–340 (1964).
   PubMedGoogle Scholar